REST is a novel prognostic factor and therapeutic target for medulloblastoma.

ABSTRACT: Medulloblastoma is a malignant pediatric brain tumor. Current treatment following patient stratification into standard and high-risk groups using clinical features has improved survival. However, a subset of patients with standard risk features have unanticipated aggressive disease, underscoring the need for a better understanding of tumor biology and the development of novel treatments. Poor differentiation, a hallmark of medulloblastomas is associated with elevated expression levels of the repressor of neuronal differentiation called repressor element 1-silencing transcription factor (REST). Here, we assessed whether elevated REST expression levels had prognostic significance and whether its pharmacologic manipulation would promote neurogenesis and block tumor cell growth. REST levels in

SUBMITTER: Taylor P 

PROVIDER: S-EPMC3763747 | biostudies-literature | 2012 Aug

REPOSITORIES: biostudies-literature